Recently, we reported the development and use of a "reverse capture" antibody microarray for the purpose of investigating antigen-autoantibody profiling. This platform was developed to allow researchers to characterize and compare the autoantibody profiles of normal and diseased patients. Our "reverse capture" protocol is based on the dualantibody sandwich immunoassay of enzyme-linked immunosorbent assay (ELISA), and we have previously reported its use to detect autoimmunity to epitopes found on native antigens derived from tumor cell lines. In this protocol, we used ovarian cancer as a model system to adapt the "reverse capture" procedure for use with native antigens derived from frozen tissue samples. The use of this platform in studies of autoimmunity is valuable because it allows for the detection of autoantibody reactivity with epitopes found on the post-translational modifications (PTMs) of native antigens, a feature not present with other protein array platforms. In the first step in the "reverse capture" process, tissue-derived native antigens are immobilized onto the 500 monoclonal antibodies that are spotted in duplicate on the array surface. Using the captured antigens as "baits," we then incubate the array with labeled IgG from test and control samples, and perform a two-slide dye-swap to account for any dye effects. Here, we present a detailed description of the "reverse capture" autoantibody microarray for use with tissue-derived native antigens.
Introduction
Autoimmunity is a key feature of many disease states. Recently, the association of autoimmunity with cancer has been well established (1-3). In cancer, host antibodies react with a unique group of autologous intracellular proteins known as tumor-associated antigens (TAAs). Additionally, autoimmunity is consistently observed in a variety of well-known autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and insulindependent diabetes mellitus. The detection of autoimmunity is useful because autoantibodies can serve as biomarkers for disease, and their presence may help to elucidate the role of significant disease-related biochemical pathways. Pervious studies of autoimmunity using microarray technology have relied on recombinant proteins and/or synthetic peptides as arrayed features (4-7). The major shortcoming of this approach is that these platforms may fail to detect the full range of autoimmunity present in a given disease state because of the absence of native protein conformations and relevant post-translational modifications (PTMs) of the arrayed features. Our laboratory recently reported on the development of a "reverse capture" autoantibody microarray (8,9). The "reverse capture" approach overcomes this significant shortcoming of other array platforms by detecting autoimmunity to proteins derived from a native source such as frozen tissue samples.
The "reverse capture" autoantibody microarray is based on the dual-antibody sandwich immunoassay of enzyme-linked immunosorbent assay (ELISA) (see Fig. 1 ). The basic platform consists of a glass microarray slide arrayed with 1000 highly specific well-characterized monoclonal antibodies against 500 unique antigens. These antibodies are used to immobilize native proteins. Because the reagents used in the procedure are non-denaturing, antigens are 
The "Reverse Capture" Autoantibody Microarray 177
immobilized on the array in their native conformations with all of their appropriate PTMs. The antigens captured on the slide then serve as "baits" for differentially labeled patient IgG samples. By labeling test and control IgG samples with different fluorescent dyes and scanning the "reverse capture" slides, it is possible to identify the target antigens to which a test sample differentially expresses autoantibodies, as compared with the control. We term this array platform a "reverse capture" autoantibody microarray, because in standard microarray nomenclature, "capture" refers to the immobilization and detection of the analyte-antigen, not the antibody. Additionally, the "reverse capture" protocol employs a two-slide dye-swap method in which the dye/sample pairings used on one microarray slide are reversed and applied to a second, parallel slide. This component of the protocol facilitates the normalization of data, and controls for differences in the labeling efficiencies of the different dyes, as well as differences in antibody-binding efficiencies following the labeling reactions.
There are several key factors we have determined that are necessary to account for in the analysis of "reverse capture" data: (a) variation in average spot AQ1 fluorescence intensity between dye channels, (b) outlying/aberrant data points, and (c) average background intensity. Accordingly, we suggest eliminating faroutlying data points and centering all data, through the method of ratio-based normalization, before determining significant autoantibody expression using a Student's t-test and hierarchical clustering. There are numerous commercially available computer programs that will assist with these types of analyses, as well as with the construction of heat maps for graphical presentation of your results. In this chapter, we describe a general normalization, transformation, and analysis method that can be carried out using any high-quality software package. We also introduce the recently developed Mixed Effect Model that can be used to account for interdependence and correlation of results.
Additional information regarding our biostatistical methods and findings using the "reverse capture" platform is available (8,10). In this chapter, we used ovarian cancer as a model system to adapt the "reverse capture" platform for use with native antigens derived from frozen tissue samples. This method, however, may be used to study differential autoantibody expression in any disease where autoimmunity is presumed to exist. This procedure should be carried out at room temperature wearing latex or nitrile examination gloves, and all reagents used in the protocol should be kept at 4°C or on ice at all times, unless otherwise specified explicitly in the protocol.
Purification of IgG using Melon™ Gel Kit
The following steps may be carried out several days before the rest of the experiment. If you have not purified IgG before the day of your "reverse capture" experiment, we recommend that you perform the purification and labeling of patient IgG during the Incubation with Native Antigens (see Subheading 3.5.); this will allow you to optimize the time spent performing this procedure. Purified IgG can be stored for up to 1 week at 4°C. If IgG is to be stored for longer than 1 week, aliquots should be placed in a -20°C freezer for storage until use; avoid repeated freeze/thaw cycles.
Equilibrate the Melon™ Gel IgG Purification Support and Purification Buffer to
room temperature (about 30 min) and swirl the bottle containing the Purification Support (do not vortex) to obtain an even suspension. To ensure proper gel slurry dispensing, use a wide bore or cut pipette tip to dispense 500 μl of gel slurry into a Handee™ Mini-Spin Column placed in a microcentrifuge tube. Swirl the bottle of gel slurry before pipetting each sample to maintain an even gel suspension. 2. Centrifuge the uncapped column/tube assemblies for 1 min at 3000 × g, then remove the spin columns and discard the flow-through. 3. Add 300 μl of Purification Buffer to the column, pulse the centrifuge for 10 s, and discard the flow-through. Repeat this wash twice. Place the bottom caps on the columns. 4. Add 50 μl of each serum sample diluted 1:10 in 1× Melon™ Gel Purification Buffer to a column. Cap the columns and incubate for 10 min at room temperature with end-over-end rotation. 5. Remove the bottom caps from the columns, loosen the top cap, and insert the spin columns into fresh 2-ml collection tubes. Then, centrifuge for 1 min at 3000 × g to collect the purified antibody in the collection tubes. 6. Set up a new column corresponding to each sample that has been purified and repeat steps 2-5 in order to further purify the collected IgG using fresh Melon™ Gel (see Note 1). 7. Measure the concentration of IgG in each purified sample using Pierce's BCA™ Protein Assay Reagent Kit. The "Reverse Capture" Autoantibody Microarray 181
Labeling of IgG with Fluorescent Dyes
The following steps may be carried out several days before the rest of the experiment. However, Subheadings 3.2 and 3.3 must be carried out together so that unbound dye is removed before storage of the labeled IgG. Labeled IgG can be stored for a maximum of 1 week at 4°C protected from light. If labeled IgG is to be stored for longer than 1 week, aliquots should be protected from light in a -20°C freezer until use. Repeated freeze/thaw cycles should be avoided.
Complete steps 1-10 rapidly without interruption. Once the DyLight™ dyes are reconstituted, they must be used immediately (see Note 3). 
Removal of Unbound Dye with Desalting Columns
As long as you work quickly, desalting can be completed at room temperature. Otherwise, if you have access to a cold room, we suggest you complete the procedure at 4°C.
1. Use two Zebra™ Desalt Spin Columns for each sample (8 columns in total) (see Note 4). 2. Twist off the bottom of each column and loosen the caps before placing each one in its collection tube and centrifuge each column at 1500 × g for 1 min to remove the storage buffer. Note the side of each column where the compacted resin is slanted upwards, and be sure to place the columns in the centrifuge with this area of the column facing outward in all subsequent centrifugations. 3. Blot the bottom of the columns against a laboratory tissue to remove excess liquid. 
U N C O R R E C T E D P R O O F

Extraction of Native Antigen from Frozen Tissue
This protocol employs the Clontech Ab Microarray 500; however, in a different capacity from that set forth by the manufacturer. Nevertheless, in order to use this microarray platform for autoantibody profiling, native antigens should be extracted from a frozen tissue sample in the exact same method set forth in Clontech's protocol. Please refer to and follow the protocol in Subheading 3.1.1 (Extracting Protein from Tissue Samples) of Chapter 9, in order to extract native antigens from your frozen tissue sample. After completing the antigen extraction, continue immediately to Subheading 3.5 (Chapter 10) of our "reverse capture" autoantibody microarray protocol (do not continue with the Clontech protocol). Also, please note that we recommend performing the native antigen extraction on the same day as the remaining portions of the "reverse capture" protocol. If proteins are extracted at an earlier time, phosphatase activity, proteolysis, and other proteolytic degradations may occur that will alter the outcome of the experiment. 
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Antibody Array Incubation with Patient IgG
The labeled IgG samples should be incubated with the microarrays in the same incubation chambers used in Subheading 3.5 for the incubation with native antigens. Some biologically relevant antigens that have not been captured by the arrays' monoclonal antibodies in Subheading 3.5 will be found on the walls of the incubation chamber. The high affinity of certain IgG molecules for these antigens' epitopes limits non-specific binding of labeled IgG to the microarray slide. 14. Proceed immediately with microarray scanning (see Subheading 3.7.). The "Reverse Capture" Autoantibody Microarray 185
Microarray Scanning and Quantitation
Antibody microarray slides should be scanned using a laser scanner, such as the Axon GenePix 4000B or the Perkin Elmer ScanArray 5000, according to the manufacturer's specifications. The scanner must be able to measure fluorescence in the ranges of the Cy3 and Cy5 fluorophores (see Note 5). You can adjust the fit of the Grid to the entire array or to individual array features using the tools on the left-hand side of the screen. 11. Carry out an Automatic Analysis using the "Alt A" command (see Note 9) and save your data as a GPR (GenePix Results) file using the "Alt U" command (see Note 10). 12. Data can be exported to Excel using the "Ctrl A" command to select all data, followed by the "Ctrl C" command to copy all data to the clipboard. 13. Data from your first slide can now be pasted into a blank Excel sheet with the "Ctrl V" command. 14. Repeat steps 9-13 using the TIFF images from your second slide (see Note 11).
Note, the same GAL file should be used to extract data from the second slide because slides provided as a pair always have the same lot number. Fig. 3 shows the scan images from a "reverse capture" experiment where the dye-swap method was employed. In this experiment, native antigens were extracted from malignant ovarian tissue and hybridized with the two microarray slides, as described. Test IgG was taken from the serum of an ovarian cancer patient, whereas control IgG was prepared from the sera of group of 20 agematched normal females; IgGs were differentially labeled. The spots that appear both green (DyLight™ 547) on one slide and red (DyLight™ 647) on the other, represent candidate antigen-autoantibody reactivities. The significance of these spots is investigated in Subheading 3.8.
Biostatistical Data Analysis
Biostatistical analyses are needed to appropriately normalize, analyze, and interpret the vast amounts of data obtained from "reverse capture" studies. There are many analysis tools to extract reliable information from microarray data [commercial software packages as well as programs provided on the web at no cost to investigators (11)]. Regardless of the tools that are employed, "reverse capture" data must be normalized and transformed before reasonable data comparisons can be made (see Note 12).
1. The raw array data acquired in GenePix Pro have to be pre-processed to separate signals from noise, eliminate low-quality measurements, handle missing values, and adjust the measured intensities to facilitate comparisons (12,13). Image analysis tools reduce the background signal and minimize the impact of poorquality spots on the final array data (11,12). The "Reverse Capture" Autoantibody Microarray 187 Fig. 3 . An illustration of results from the two-slide dye-swap. In Mix 1, control IgG is labeled with DyLight™ 647 dye (red) and ovarian cancer patient IgG is labeled with DyLight™ 547 dye (green). In Mix 2, the dyes are swapped, so control IgG fluoresces green, whereas ovarian cancer IgG fluoresces red. A portion of each array slide is enlarged to clearly illustrate that green spots denoting ovarian cancer autoantibody reactivity in Mix 1, fluoresce red in Mix 2.
2. The simplest method of normalization is a linear transformation of the data to correct for experimental variability because of differences in sample quantity, fluorescent labeling, hybridization efficiencies, and inter-array variations (14-16).
a. General linear modeling methods such as ANOVA (17) or a mixed model (18) protocol can be used to link the normalization process with downstream data analysis. b. Non-linear normalization approaches, such as locally weighted regression, are useful for removing intensity-dependent effects on the fluorescence ratios (16,19,20) .
3. Other data transformation procedures such as intensity-based filtering and replicate filtering can increase the reliability of measurements and assist with downstream clustering. For our dye-swapped replicate data, backgroundsubtracted Log 2 -transformed intensity ratios of the dye-swapping slides can be plotted against each other; outliers with more than two standard deviations should then be excluded from clustering analysis. 6. For a "supervised" approach to building a classifier suitable for diagnosis, as well as drug discovery, support vector machine (SVM) methods based on a backward selection procedure known as recursive feature elimination (RFE) have been developed to select a small subset of significant data points from broad patterns of data (30,31). Data points are ranked in relative importance as markers on the basis of the absolute values of their fitted coefficients in the linear form of the classifier for an SVM formed with linear kernel (30). In estimating the error rate of the classifier based on a smaller set of significant parameters, care must be taken to ensure that the selection bias associated with choosing the optimal of parameters has been assessed and corrected for, using either an "external" cross-validation or a bootstrap approach (32). 7. Another method for identifying biomarkers from a very large number of candidates is to rank antigen-autoantibody reactivities using a supervised selection procedure that makes use of known clinical data such as survival time, time to distant metastases, or time to recurrence of tumor (33,34).
U N C O R R E C T E D P R O O F
Notes
1. The IgG purification procedure is repeated in order to ensure exclusive isolation of IgG from patient sera. We have found that with only one purification run, high-abundance proteins other than IgG may be present in the eluted solution. 2. To label the purified antibodies with fluorescent dyes, the antibodies must be in a buffer free of ammonium ions and primary amines. The Melon™ Gel Purification
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Buffer used in Subheading 3.1 is compatible with all of the DyLight™ labeling reagents used in Subheading 3.2. 3. Pierce Biotechnology supplies the DyLight™ 547 and DyLight™ 647 dyes as monofunctional N-hydroxysuccinimide (NHS)-esters in dried pre-measured amounts. The NHS-ester is a functional group that cross-links to primary amines. This reaction releases the NHS group and produces a covalent amide bond that links the dye to the amine. Because of the unique affinity ratio of each dye to the antibody that it is labeling, different volumes of the two dyes are used in the labeling reactions. Once reconstituted in the DMF supplied in the DyLight™ labeling kits, unused aliquots of the DyLight™ dyes cannot be saved for future use. The binding efficiency is quickly diminished in this medium. If you wish to save unused portions of the dyes for later use, they should initially be reconstituted in anhydrous DMF (or DMSO) and frozen at -20°C until use. 4. The Zebra™ Desalt Spin Columns that come with the DyLight™ Labeling Kits remove free dye. These columns contain a desalting resin and molecular weight cutoff. They perform well in desalting small sample volumes, providing excellent protein recovery and ≥ 95% retention of small molecules and salts (<7 kDa). 5. The excitation and emission maxima of the more commonly used CyDye fluorophores are very close to those of the DyLight™ dyes, where DyLight™ 547 is analogous to Cy3 and DyLight™ 647 is analogous to Cy5. Thus, the preprogrammed settings for the scanning of CyDyes may be used in scanning arrays labeled with the Pierce DyLight™ dyes. 6. There are various software packages available for creating scan and quantitation protocols. ScanArray Express by Packard Bioscience or GenePix Pro 6.0 by Molecular Devices is recommended for the scanning of the microarray slides. GenePix Pro is recommended for the quantitation of your results. 7. The microarray may need to be scanned several times before the ideal laser power and PMT settings are ascertained. If your scanner has the option of running an Automatic Sensitivity Calibration, this option may be perused. We recommend that you also refer to our published "reverse capture" troubleshooting tips for additional suggestions (9). 8. If the images will be displayed as graphics in a presentation or article, they should be saved individually as BMP files and then readjusted and/or overlayed in a photo-editing program, such as Adobe Photoshop™. 9. The tab labeled "Histogram" at the top of the screen allows you to check the normalization of your data. When dye and scanning intensities are perfectly normalized, the Count Ratio will be equal to 1.0. If your Count Ratio deviates significantly from 1.0, you should attempt to adjust the PMT gains used for scanning so that this value approximates 1.0. The "Scatter Plot" tab allows you to view the distribution of your data to ensure that there are a minimal number of outlying data points. 10. GPR files are used in some biostatistical analyses. For example, the microarray data analysis software in order to perform data manipulation and analyses, including ratio-based normalization, lowess normalization, hierarchical clustering, non-hierarchical clustering, and t-tests for statistical significance. 11. When opening the TIFF files from the second slide, it is necessary to check the box next to "Replace current images" in the "Open Images" dialogue box. 12. Normalization and transformation of data accomplish two aims. First, logtransformation of data scales the range of your data; as "reverse capture" data is acquired in ratio form, it is important that the scale allows for equal differential expression by the sample represented in both the numerator and the denominator of the ratio. Second, normalization centers data around an expected mean value; log-transformed data are centered around the expected median (or mean) log-ratio of 0.0 across all data points. 
